J Gynecol Oncol.  2010 Sep;21(3):151-162. 10.3802/jgo.2010.21.3.151.

Current status in the management of uterine corpus cancer in Korea

• Jeong NH
• Lee JM
• Lee SK

• KMID: 1980851
• DOI: http://doi.org/10.3802/jgo.2010.21.3.151

Abstract

Uterine corpus cancer has increased in prevalence in Korean women over the last decade. Recently, elegant studies have been reported from many institutes. To improve treatment strategies, a review of our own data is warranted. This work will discuss the risks and prognostic factors for uterine corpus cancer, and the radiologic evaluation, prediction of lymph node metastasis, systematic lymphadenectomy, minimally invasive surgery, ovarian-saving surgery, fertility-sparing treatment, and adjuvant treatment in women with uterine cancer.

Keyword

Uterine neoplasms; Review

MeSH Terms

Academies and Institutes
Female
Humans
Korea
Lymph Node Excision
Lymph Nodes
Neoplasm Metastasis
Prevalence
Uterine Neoplasms

Reference

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999. 80:827–841.

2. SOG Gynecologic Oncology Committee. Annual report of gynecologic cancer registry program in Korea for 2004 (Jan. 1st, 2004-Dec. 31st, 2004). Korean J Obstet Gynecol. 2007. 50:28–78.

3. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006. 20:207–225.

4. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002. 11:1531–1543.

5. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer. 2008. 98:1582–1585.

6. Bjorge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007. 120:378–383.

7. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003. 104:669–676.

8. Goodman MT, Hankin JH, Wilkens LR, Lyu LC, McDuffie K, Liu LQ, et al. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res. 1997. 57:5077–5085.

9. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci. 2009. 24:995–1003.

10. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005. 106:413–425.

11. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009. 105:103–104.

12. Mohan DS, Samuels MA, Selim MA, Shalodi AD, Ellis RJ, Samuels JR, et al. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol Oncol. 1998. 70:165–171.

13. Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005. 23:3668–3675.

14. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008. 100:1707–1716.

15. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009. 373:125–136.

16. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000. 355:1404–1411.

17. Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009. 373:137–146.

18. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000. 21:427–433.

19. Jeong NH, Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, et al. Role of body mass index as a risk and prognostic factor of endometrioid uterine cancer in Korean women. Gynecol Oncol. 2010. 118:24–28.

20. Xu WH, Dai Q, Xiang YB, Zhao GM, Ruan ZX, Cheng JR, et al. Nutritional factors in relation to endometrial cancer: a report from a population-based case-control study in Shanghai, China. Int J Cancer. 2007. 120:1776–1781.

21. McCann SE, Freudenheim JL, Marshall JR, Brasure JR, Swanson MK, Graham S. Diet in the epidemiology of endometrial cancer in western New York (United States). Cancer Causes Control. 2000. 11:965–974.

22. Jeong NH, Song ES, Lee JM, Lee KB, Kim MK, Yun YM, et al. Preoperative levels of plasma micronutrients are related to endometrial cancer risk. Acta Obstet Gynecol Scand. 2009. 88:434–439.

23. Lee KH, Lee JK, Kim JH, Lee JM, Song ES, Kim MK. Folic acid and vitamin B12 intake in relation to risk of endometrial cancer: case-control study. Korean J Obstet Gynecol. 2008. 51:1103–1111.

24. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther. 2008. 8:1159–1167.

25. Lee JM, Lee JH, Tong SY, Ki KD, Lee SK, Huh CY. The effect of HER-2 polymorphism according to age on the risk and pathologic feature of endometrial cancer. Korean J Obstet Gynecol. 2009. 52:529–537.

26. Roh JW, Kim JW, Park NH, Song YS, Park IA, Park SY, et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol. 2004. 93:499–505.

27. Kang S, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Cyclin D1 polymorphism and the risk of endometrial cancer. Gynecol Oncol. 2005. 97:431–435.

28. Jo H, Kang S, Kim SI, Kim JW, Park NH, Song YS, et al. The C19007T polymorphism of ERCC1 and its correlation with the risk of epithelial ovarian and endometrial cancer in Korean womenL a case control study. Gynecol Obstet Invest. 2007. 64:84–88.

29. Tong SY, Ha SY, Ki KD, Lee JM, Lee SK, Lee KB, et al. The effects of obesity and HER-2 polymorphisms as risk factors for endometrial cancer in Korean women. BJOG. 2009. 116:1046–1052.

30. Lee KB, Ki KD, Lee JM, Lee JK, Kim JW, Cho CH, et al. The risk of lymph node metastasis based on myometrial invasion and tumor grade in endometrioid uterine cancers: a multicenter, retrospective Korean study. Ann Surg Oncol. 2009. 16:2882–2887.

31. Chung HH, Kang SB, Cho JY, Kim JW, Park NH, Song YS, et al. Accuracy of MR imaging for the prediction of myometrial invasion of endometrial carcinoma. Gynecol Oncol. 2007. 104:654–659.

32. Park JY, Kim EN, Kim DY, Suh DS, Kim JH, Kim YM, et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol. 2008. 108:486–492.

33. Yoo SC, Kim WY, Yoon JH, Kim HY, Lee EJ, Chang SJ, et al. Accuracy of preoperative magnetic resonance imaging in assessing lymph node metastasis and myometrial invasion in patients with uterine cancer. Eur J Gynaecol Oncol. 2009. 30:167–170.

34. Han SS, Lee SH, Kim DH, Kim JW, Park NH, Kang SB, et al. Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer. Acta Obstet Gynecol Scand. 2010. 89:168–174.

35. Cho H, Kim YT, Kim JH. Accuracy of preoperative tests in clinical stage I endometrial cancer: the importance of lymphadenectomy. Acta Obstet Gynecol Scand. 2010. 89:175–181.

36. Choi YS, Koh SB, Ahn JY, Yi CM, Shin IH, Lee TS. Usefulness of preoperative CA 125 level in decision making of lymphadenectomy in endometrial cancer patients. Korean J Obstet Gynecol. 2005. 48:2877–2887.

37. Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006. 85:1501–1505.

38. Selman TJ, Mann CH, Zamora J, Khan KS. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health. 2008. 8:8.

39. Girardi F, Petru E, Heydarfadai M, Haas J, Winter R. Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol Oncol. 1993. 49:177–180.

40. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 1987. 60:2035–2041.

41. Kim SH, Kim HD, Song YS, Kang SB, Lee HP. Detection of deep myometrial invasion in endometrial carcinoma: comparison of transvaginal ultrasound, CT, and MRI. J Comput Assist Tomogr. 1995. 19:766–772.

42. Ahn JY, Yi CM, Lee TS, Koh SB, Park YC, Jung KJ, et al. Analysis of factors to affect on MR assessment of myometrial invasion and cervical involvement in endometrial cancer. Korean J Obstet Gynecol. 2006. 49:113–121.

43. Hwang JH, Lee NW, Lee KW, Lee JK. Magnetic resonance imaging for assessment of deep endometrial invasion for patients with endometrial carcinoma. Aust N Z J Obstet Gynaecol. 2009. 49:537–541.

44. Suh DS, Kim JK, Kim KR, Kim DY, Kim JH, Kim YM, et al. Reliability of magnetic resonance imaging in assessing myometrial invasion absence in endometrial carcinoma. Acta Obstet Gynecol Scand. 2009. 88:990–993.

45. Hacker NF. Berek JS, Hacker NF, editors. Uterine cancer. Berek & Hacker's gynecologic oncology. 2010. 5th ed. Philadelphia: Lippincott Williams & Wilkins;400–417.

46. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 1995. 56:29–33.

47. Chan JK, Wu H, Cheung MK, Shin JY, Osann K, Kapp DS. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol. 2007. 106:282–288.

48. Lee TS, Kim JW, Kim TJ, Cho CH, Ryu SY, Ryu HS, et al. Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group. Gynecol Oncol. 2009. 115:26–31.

49. Tangjitgamol S, Anderson BO, See HT, Lertbutsayanukul C, Sirisabya N, Manchana T, et al. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009. 10:1119–1127.

50. Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, Park SY, et al. Current status in the management of uterine cancer in Korea: a multi-center retrospective Korean study. The 25th Annual Meeting of Korean Society of Gynecologic Oncology and Colposcopy 2010. Abstract 10S-006.

51. Seo MW, Lee HY, Kim DY, Suh DS, Kim JH, Kim YM, et al. The effect of lymphadenectomy on the survival rate of clinical stage I endometrial cancer. Korean J Gynecol Oncol. 2006. 17:227–233.

52. Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS. Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma. Acta Obstet Gynecol Scand. 2008. 87:1361–1369.

53. Fujimoto T, Nanjyo H, Nakamura A, Yokoyama Y, Takano T, Shoji T, et al. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer. Gynecol Oncol. 2007. 107:253–259.

54. Childers JM, Brzechffa PR, Hatch KD, Surwit EA. Laparoscopically assisted surgical staging (LASS) of endometrial cancer. Gynecol Oncol. 1993. 51:33–38.

55. Jung YW, Lee DW, Kim SW, Nam EJ, Kim JH, Kim JW, et al. Robot-assisted staging using three robotic arms for endometrial cancer: comparison to laparoscopy and laparotomy at a single institution. J Surg Oncol. 2010. 101:116–121.

56. Hahn HS, Kim HJ, Yoon SG, Kim WC, Choi HJ, Kim HS, et al. Laparoscopy-assisted vaginal versus abdominal hysterectomy in endometrial cancer. Int J Gynecol Cancer. 2010. 20:102–109.

57. Lee JH, Jung US, Kyung MS, Choi JS. Laparoscopic-assisted staging surgery for Korean women with endometrial cancer. JSLS. 2008. 12:150–155.

58. Cho YH, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Laparoscopic management of early uterine cancer: 10-year experience in Asan Medical Center. Gynecol Oncol. 2007. 106:585–590.

59. Lee TS, Kim JW, Kim SH, Seong SJ, Song ES, Kim JH, et al. Surgical practice patterns in endometrial cancer: results of the Korean Gynecologic Oncology Group survey. J Gynecol Oncol. 2009. 20:107–112.

60. Lim S, Kim HS, Lee KB, Yoo CW, Park SY, Seo SS. Does the use of a uterine manipulator with an intrauterine balloon in total laparoscopic hysterectomy facilitate tumor cell spillage into the peritoneal cavity in patients with endometrial cancer? Int J Gynecol Cancer. 2008. 18:1145–1149.

61. Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984. 63:825–832.

62. Lee TS, Jung JY, Kim JW, Park NH, Song YS, Kang SB, et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. Gynecol Oncol. 2007. 104:52–57.

63. Han CH, Lim SY, Kook IY, Lee KH, Namkoong SE, Park JS, et al. Prognostic outcome of patients with clinical stage I-II endometrial cancer according to bilateral salpino-oophorectomy. Korean J Obstet Gynecol. 2007. 50:288–294.

64. Yoo SC, Yoon JH, Kim WY, Chang SJ, Joo HJ, Chang KH, et al. Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery. J Gynecol Oncol. 2009. 20:181–186.

65. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003. 89:201–209.

66. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004. 92:744–751.

67. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG. 2007. 114:1313–1320.

68. Kim S, Wu HG, Lee HP, Kang SB, Song YS, Park NH, et al. Patterns of failure after postoperative radiation therapy for endometrial carcinoma. Cancer Res Treat. 2006. 38:133–138.

69. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006. 24:36–44.

70. Hogberg T, Rosenberg P, Kristensen G, de Oliveira CF, de Pont Christensen R, Sorbe B, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol. 2007. 25(18S):5503.

71. Kim JH, Lee SJ, Bae JH, Lee SH, Bae SN, Namkoong SE, et al. Adjuvant therapy in high-risk early endometrial carcinoma: a retrospective analysis of 46 cases. J Gynecol Oncol. 2008. 19:236–240.

72. Choi MC, Park JH, Kim SH, Jun KH, Jung SG, Na YJ, et al. Comparison of postoperative radiotherapy versus postoperative paclitaxel and platinum chemotherapy in uterine endometrial carcinoma. Korean J Obstet Gynecol. 2008. 51:1280–1287.

73. Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003. 102:718–725.

74. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007. 25:2798–2803.

75. Park JC, Cho CH, Rhee JH. A successful live birth through in vitro fertilization program after conservative treatment of FIGO grade I endometrial cancer. J Korean Med Sci. 2006. 21:567–571.

76. Cho YH, Suh DS, Ji YI, Kim DY, Kim JH, Kim YM, et al. Treatment efficacy of high dose progestin in young women with early stage of endometrial carcinoma. Korean J Obstet Gynecol. 2007. 50:486–493.

77. Han AR, Kwon YS, Kim DY, Kim JH, Kim YM, Kim YT, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer. 2009. 19:147–151.

78. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009. 19:1068–1073.

79. Kizer NT, Zighelboim I, Case AS, Dewdney SB, Thaker PH, Massad LS. The role of PET/CT in the management of patients with cervical cancer: practice patterns of the members of the Society of Gynecologic Oncologists. Gynecol Oncol. 2009. 114:310–314.

80. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging. 2008. 35:1081–1088.

81. Park JY, Kim EN, Kim DY, Kim JH, Kim YM, Kim YT, et al. Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients. Int J Gynecol Cancer. 2008. 18:1332–1338.

82. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS. 2009. 117:693–707.

83. Jeon YT, Kang S, Kang DH, Yoo KY, Park IA, Bang YJ, et al. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2004. 13:1538–1542.

84. No JH, Jeon YT, Park IA, Kang D, Kim JW, Park NH, et al. Expression of mTOR protein and its clinical significance in endometrial cancer. Med Sci Monit. 2009. 15:BR301–BR305.

85. Cho H, Kang ES, Kim YT, Kim JH. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest. 2009. 27:313–323.

86. Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, et al. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol. 2010. 116:533–538.

87. An HJ, Kim KI, Kim JY, Shim JY, Kang H, Kim TH, et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol. 2007. 31:846–853.

88. Kim JW, Song JY, Lee JM, Lee JK, Lee NW, Yeom BW, et al. Expression of pituitary tumor-transforming gene in endometrial cancer as a prognostic marker. Int J Gynecol Cancer. 2008. 18:1352–1359.

89. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med. 2005. 50:585–590.

90. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004. 90:1877–1881.

91. Ji YI, Kim MK, Kim DY, Suh DS, Kim JH, Kim YM, et al. Clinical analysis of recurrent and advanced saged endometrial cancer. Korean J Gynecol Oncol Colposc. 2004. 15:294–300.

92. Choi ES, Jung MH, Ma GY, Lee SJ, Kim DY, Kim JH, et al. The efficacy of paclitaxel based combination chemotherapy in recurrent endometrial cancer. Korean J Gynecol Oncol. 2005. 16:163–168.

93. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986. 67:326–330.

94. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol. 1996. 175:1195–1200.

95. Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol. 2001. 97:555–560.

96. Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer. 2006. 16:805–808.

97. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006. 24:587–592.

98. Lee KB, Lee JM, Lee JK, Cho CH. Endometrial cancer patients and tibolone: a matched case-control study. Maturitas. 2006. 55:264–269.